Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04163783 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04163783: Completed Phase 1 study, sponsored by BeiGene.
NCT04163783 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04163783, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Phase 1 study in healthy subjects to determine the effect of an 8-hour fast from food on the pharmacokinetics of \[14C\]-BGB-3111.
Interventions
- DRUG BGB-3111
- DRUG [14C]-BGB-3111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2017-04-18 |
| Phase | Phase 1 |
What the finished NCT04163783 record still lists
NCT04163783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which BGB-3111 is the first listed.
NCT04163783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04163783 about?
NCT04163783 is a clinical study titled "Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males". Phase 1 study in healthy subjects to determine the effect of an 8-hour fast from food on the pharmacokinetics of \[14C\]-BGB-3111.
What is the current status of trial NCT04163783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-03-29. Estimated completion is 2017-04-18.
What interventions are being tested in trial NCT04163783?
The interventions under investigation include: BGB-3111 (DRUG), [14C]-BGB-3111 (DRUG).
Who is sponsoring clinical trial NCT04163783?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04163783's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI